Cargando…

Molecular Mechanisms Related with Oligometastatic Prostate Cancer—Is It Just a Matter of Numbers?

SIMPLE SUMMARY: Oligometastatic prostate cancer represents a transitional state between localized and widespread metastatic disease and it is defined by presence of five or fewer metastatic sites. In the current narrative review, we provide an overview of the current treatment landscape of oligometa...

Descripción completa

Detalles Bibliográficos
Autores principales: Surcel, Cristian, Kretschmer, Alexander, Mirvald, Cristian, Sinescu, Ioanel, Heidegger, Isabel, Tsaur, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833728/
https://www.ncbi.nlm.nih.gov/pubmed/35159033
http://dx.doi.org/10.3390/cancers14030766
Descripción
Sumario:SIMPLE SUMMARY: Oligometastatic prostate cancer represents a transitional state between localized and widespread metastatic disease and it is defined by presence of five or fewer metastatic sites. In the current narrative review, we provide an overview of the current treatment landscape of oligometastatic cancer, focusing on the current biomarkers used in the identification of true oligometastatic disease and highlighting the impact of molecular imaging on stage shift in different scenarios. Finally, we address current and future directions regarding the use of genetic and epigenetic targeting treatments in oligometastatic prostate cancer. ABSTRACT: During the last decade, the body of knowledge regarding the oligometastatic state has increased exponentially. Several molecular frameworks have been established, aiding our understanding of metastatic spread caused by genetically unstable cells that adapt to a tissue environment which is distant from the primary tumor. In the current narrative review, we provide an overview of the current treatment landscape of oligometastatic cancer, focusing on the current biomarkers used in the identification of true oligometastatic disease and highlighting the impact of molecular imaging on stage shift in different scenarios. Finally, we address current and future directions regarding the use of genetic and epigenetic targeting treatments in oligometastatic prostate cancer.